ID   ROCK1_HUMAN             Reviewed;        1354 AA.
AC   Q13464; B0YJ91; Q2KHM4; Q59GZ4;
DT   24-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=Rho-associated protein kinase 1;
DE            EC=2.7.11.1;
DE   AltName: Full=Renal carcinoma antigen NY-REN-35;
DE   AltName: Full=Rho-associated, coiled-coil-containing protein kinase 1;
DE   AltName: Full=Rho-associated, coiled-coil-containing protein kinase I;
DE            Short=ROCK-I;
DE   AltName: Full=p160 ROCK-1;
DE            Short=p160ROCK;
GN   Name=ROCK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 187-195; 281-288;
RP   465-473; 818-828; 885-893 AND 934-945, FUNCTION, PHOSPHORYLATION,
RP   INTERACTION WITH RHOA, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Leukemia;
RX   PubMed=8617235;
RA   Ishizaki T., Maekawa M., Fujisawa K., Okawa K., Iwamatsu A.,
RA   Fujita A., Watanabe N., Saito Y., Kakizuka A., Morii N., Narumiya S.;
RT   "The small GTP-binding protein Rho binds to and activates a 160 kDa
RT   Ser/Thr protein kinase homologous to myotonic dystrophy kinase.";
RL   EMBO J. 15:1885-1893(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-13; 85-94; 327-334; 405-415 AND 546-563,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT SER-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Ramsay A., Leung H.Y.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 323-1027.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   ROLE IN SMOOTH MUSCLE CONTRACTION.
RX   PubMed=9722579; DOI=10.1074/jbc.273.36.23433;
RA   Van Eyk J.E., Arrell D.K., Foster D.B., Strauss J.D., Heinonen T.Y.,
RA   Furmaniak-Kazmierczak E., Cote G.P., Mak A.S.;
RT   "Different molecular mechanisms for Rho family GTPase-dependent, Ca2+-
RT   independent contraction of smooth muscle.";
RL   J. Biol. Chem. 273:23433-23439(1998).
RN   [7]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [8]
RP   FUNCTION, INTERACTION WITH LIMK1 AND LIMK2, AND INHIBITION BY Y-27632.
RX   PubMed=10436159; DOI=10.1126/science.285.5429.895;
RA   Maekawa M., Ishizaki T., Boku S., Watanabe N., Fujita A., Iwamatsu A.,
RA   Obinata T., Ohashi K., Mizuno K., Narumiya S.;
RT   "Signaling from Rho to the actin cytoskeleton through protein kinases
RT   ROCK and LIM-kinase.";
RL   Science 285:895-898(1999).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH LIMK1.
RX   PubMed=10652353; DOI=10.1074/jbc.275.5.3577;
RA   Ohashi K., Nagata K., Maekawa M., Ishizaki T., Narumiya S., Mizuno K.;
RT   "Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation
RT   at threonine 508 within the activation loop.";
RL   J. Biol. Chem. 275:3577-3582(2000).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH LIMK2.
RX   PubMed=11018042; DOI=10.1074/jbc.M007074200;
RA   Sumi T., Matsumoto K., Nakamura T.;
RT   "Specific activation of LIM kinase 2 via phosphorylation of threonine
RT   505 by ROCK, a Rho-dependent protein kinase.";
RL   J. Biol. Chem. 276:670-676(2001).
RN   [11]
RP   CLEAVAGE BY CASPASE-3, MUTAGENESIS OF ASP-1113, INTERACTION WITH
RP   PPP1R12A, AND FUNCTION.
RX   PubMed=11283607; DOI=10.1038/35070019;
RA   Sebbagh M., Renvoize C., Hamelin J., Riche N., Bertoglio J.,
RA   Breard J.;
RT   "Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and
RT   apoptotic membrane blebbing.";
RL   Nat. Cell Biol. 3:346-352(2001).
RN   [12]
RP   INTERACTION WITH GEM.
RX   PubMed=11956230; DOI=10.1083/jcb.200111026;
RA   Ward Y., Yap S.-F., Ravichandran V., Matsumura F., Ito M.,
RA   Spinelli B., Kelly K.;
RT   "The GTP binding proteins Gem and Rad are negative regulators of the
RT   Rho-Rho kinase pathway.";
RL   J. Cell Biol. 157:291-302(2002).
RN   [13]
RP   INTERACTION WITH RHOE AND PPP1R12A, AND SUBCELLULAR LOCATION.
RX   PubMed=12773565; DOI=10.1128/MCB.23.12.4219-4229.2003;
RA   Riento K., Guasch R.M., Garg R., Jin B., Ridley A.J.;
RT   "RhoE binds to ROCK I and inhibits downstream signaling.";
RL   Mol. Cell. Biol. 23:4219-4229(2003).
RN   [14]
RP   REVIEW.
RX   PubMed=12778124; DOI=10.1038/nrm1128;
RA   Riento K., Ridley A.J.;
RT   "Rocks: multifunctional kinases in cell behaviour.";
RL   Nat. Rev. Mol. Cell Biol. 4:446-456(2003).
RN   [15]
RP   INTERACTION WITH TSG101.
RX   PubMed=17853893; DOI=10.1038/sj.emboj.7601850;
RA   Morita E., Sandrin V., Chung H.Y., Morham S.G., Gygi S.P.,
RA   Rodesch C.K., Sundquist W.I.;
RT   "Human ESCRT and ALIX proteins interact with proteins of the midbody
RT   and function in cytokinesis.";
RL   EMBO J. 26:4215-4227(2007).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH DAPK3.
RX   PubMed=17158456; DOI=10.1074/jbc.M609990200;
RA   Hagerty L., Weitzel D.H., Chambers J., Fortner C.N., Brush M.H.,
RA   Loiselle D., Hosoya H., Haystead T.A.;
RT   "ROCK1 phosphorylates and activates zipper-interacting protein
RT   kinase.";
RL   J. Biol. Chem. 282:4884-4893(2007).
RN   [17]
RP   FUNCTION, INTERACTION WITH FHOD1, AND SUBCELLULAR LOCATION.
RX   PubMed=18694941; DOI=10.1074/jbc.M801800200;
RA   Hannemann S., Madrid R., Stastna J., Kitzing T., Gasteier J.,
RA   Schoenichen A., Bouchet J., Jimenez A., Geyer M., Grosse R.,
RA   Benichou S., Fackler O.T.;
RT   "The diaphanous-related formin FHOD1 associates with ROCK1 and
RT   promotes Src-dependent plasma membrane blebbing.";
RL   J. Biol. Chem. 283:27891-27903(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1105, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH PFN1.
RX   PubMed=18573880; DOI=10.1128/MCB.00079-08;
RA   Shao J., Welch W.J., Diprospero N.A., Diamond M.I.;
RT   "Phosphorylation of profilin by ROCK1 regulates polyglutamine
RT   aggregation.";
RL   Mol. Cell. Biol. 28:5196-5208(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH JIP3.
RX   PubMed=19036714; DOI=10.1126/scisignal.1161938;
RA   Ongusaha P.P., Qi H.H., Raj L., Kim Y.B., Aaronson S.A., Davis R.J.,
RA   Shi Y., Liao J.K., Lee S.W.;
RT   "Identification of ROCK1 as an upstream activator of the JIP-3 to JNK
RT   signaling axis in response to UVB damage.";
RL   Sci. Signal. 1:RA14-RA14(2008).
RN   [22]
RP   FUNCTION.
RX   PubMed=19181962; DOI=10.1152/ajpheart.01038.2008;
RA   Kroll J., Epting D., Kern K., Dietz C.T., Feng Y., Hammes H.P.,
RA   Wieland T., Augustin H.G.;
RT   "Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven
RT   retinal neovascularization and sprouting angiogenesis.";
RL   Am. J. Physiol. 296:H893-H899(2009).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH PPP1R12A.
RX   PubMed=19131646; DOI=10.1161/CIRCRESAHA.108.188524;
RA   Wang Y., Zheng X.R., Riddick N., Bryden M., Baur W., Zhang X.,
RA   Surks H.K.;
RT   "ROCK isoform regulation of myosin phosphatase and contractility in
RT   vascular smooth muscle cells.";
RL   Circ. Res. 104:531-540(2009).
RN   [24]
RP   FUNCTION.
RX   PubMed=19997641; DOI=10.1371/journal.pone.0008190;
RA   Lock F.E., Hotchin N.A.;
RT   "Distinct roles for ROCK1 and ROCK2 in the regulation of keratinocyte
RT   differentiation.";
RL   PLoS ONE 4:E8190-E8190(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1105, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-647, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [27]
RP   INTERACTION WITH CHORDC1.
RX   PubMed=20230755; DOI=10.1016/j.devcel.2009.12.020;
RA   Ferretti R., Palumbo V., Di Savino A., Velasco S., Sbroggio M.,
RA   Sportoletti P., Micale L., Turco E., Silengo L., Palumbo G.,
RA   Hirsch E., Teruya-Feldstein J., Bonaccorsi S., Pandolfi P.P.,
RA   Gatti M., Tarone G., Brancaccio M.;
RT   "Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication
RT   and tumorigenesis.";
RL   Dev. Cell 18:486-495(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   FUNCTION, AND CLEAVAGE BY CASPASE-3.
RX   PubMed=21072057; DOI=10.1038/cdd.2010.140;
RA   Gabet A.S., Coulon S., Fricot A., Vandekerckhove J., Chang Y.,
RA   Ribeil J.A., Lordier L., Zermati Y., Asnafi V., Belaid Z., Debili N.,
RA   Vainchenker W., Varet B., Hermine O., Courtois G.;
RT   "Caspase-activated ROCK-1 allows erythroblast terminal maturation
RT   independently of cytokine-induced Rho signaling.";
RL   Cell Death Differ. 18:678-689(2011).
RN   [30]
RP   REVIEW.
RX   PubMed=20803696; DOI=10.1002/cm.20472;
RA   Amano M., Nakayama M., Kaibuchi K.;
RT   "Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell
RT   polarity.";
RL   Cytoskeleton 67:545-554(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1328, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 947-1015 IN COMPLEX WITH
RP   RHOA.
RX   PubMed=14660612; DOI=10.1074/jbc.M311911200;
RA   Dvorsky R., Blumenstein L., Vetter I.R., Ahmadian M.R.;
RT   "Structural insights into the interaction of ROCKI with the switch
RT   regions of RhoA.";
RL   J. Biol. Chem. 279:7098-7104(2004).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 6-415, AND SUBUNIT.
RX   PubMed=16249185; DOI=10.1074/jbc.M508847200;
RA   Jacobs M., Hayakawa K., Swenson L., Bellon S., Fleming M., Taslimi P.,
RA   Doran J.;
RT   "The structure of dimeric ROCK I reveals the mechanism for ligand
RT   selectivity.";
RL   J. Biol. Chem. 281:260-268(2006).
RN   [37]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-108; SER-773; PRO-1112; SER-1193;
RP   GLU-1217; GLN-1262 AND ARG-1264.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein kinase which is a key regulator of actin
CC       cytoskeleton and cell polarity. Involved in regulation of smooth
CC       muscle contraction, actin cytoskeleton organization, stress fiber
CC       and focal adhesion formation, neurite retraction, cell adhesion
CC       and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2,
CC       MYL9/MLC2, PFN1 and PPP1R12A. Phosphorylates FHOD1 and acts
CC       synergistically with it to promote SRC-dependent non-apoptotic
CC       plasma membrane blebbing. Phosphorylates JIP3 and regulates the
CC       recruitment of JNK to JIP3 upon UVB-induced stress. Acts as a
CC       suppressor of inflammatory cell migration by regulating PTEN
CC       phosphorylation and stability. Acts as a negative regulator of
CC       VEGF-induced angiogenic endothelial cell activation. Required for
CC       centrosome positioning and centrosome-dependent exit from mitosis.
CC       Plays a role in terminal erythroid differentiation. May regulate
CC       closure of the eyelids and ventral body wall by inducing the
CC       assembly of actomyosin bundles. Promotes keratinocyte terminal
CC       differentiation. Involved in osteoblast compaction through the
CC       fibronectin fibrillogenesis cell-mediated matrix assembly process,
CC       essential for osteoblast mineralization.
CC       {ECO:0000269|PubMed:10436159, ECO:0000269|PubMed:10652353,
CC       ECO:0000269|PubMed:11018042, ECO:0000269|PubMed:11283607,
CC       ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18573880,
CC       ECO:0000269|PubMed:18694941, ECO:0000269|PubMed:19036714,
CC       ECO:0000269|PubMed:19131646, ECO:0000269|PubMed:19181962,
CC       ECO:0000269|PubMed:19997641, ECO:0000269|PubMed:21072057,
CC       ECO:0000269|PubMed:8617235, ECO:0000269|PubMed:9722579}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by RHOA binding. Inhibited by Y-
CC       27632.
CC   -!- SUBUNIT: Homodimer. Interacts with RHOB, RHOC, MYLC2B and PTEN.
CC       Interacts with ITGB1BP1 (via N-terminus and PTB domain) (By
CC       similarity). Interacts with RHOA (activated by GTP), CHORDC1,
CC       DAPK3, GEM, JIP3, RHOE, PPP1R12A, PFN1, LIMK1, LIMK2 and TSG101.
CC       Interacts with FHOD1 in a Src-dependent manner. {ECO:0000250,
CC       ECO:0000269|PubMed:10436159, ECO:0000269|PubMed:10652353,
CC       ECO:0000269|PubMed:11018042, ECO:0000269|PubMed:11283607,
CC       ECO:0000269|PubMed:11956230, ECO:0000269|PubMed:12773565,
CC       ECO:0000269|PubMed:14660612, ECO:0000269|PubMed:16249185,
CC       ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:17853893,
CC       ECO:0000269|PubMed:18573880, ECO:0000269|PubMed:18694941,
CC       ECO:0000269|PubMed:19036714, ECO:0000269|PubMed:19131646,
CC       ECO:0000269|PubMed:20230755, ECO:0000269|PubMed:8617235}.
CC   -!- INTERACTION:
CC       Q8IYR0:CFAP206; NbExp=3; IntAct=EBI-876651, EBI-749051;
CC       Q86V42:FAM124A; NbExp=3; IntAct=EBI-876651, EBI-744506;
CC       Q7Z6J6:FRMD5; NbExp=4; IntAct=EBI-876651, EBI-727282;
CC       P25791:LMO2; NbExp=3; IntAct=EBI-876651, EBI-739696;
CC       O15481:MAGEB4; NbExp=3; IntAct=EBI-876651, EBI-751857;
CC       Q13203:MYBPH; NbExp=2; IntAct=EBI-876651, EBI-5655165;
CC       Q9BUI4:POLR3C; NbExp=3; IntAct=EBI-876651, EBI-5452779;
CC       P61586:RHOA; NbExp=4; IntAct=EBI-876651, EBI-446668;
CC       Q99816:TSG101; NbExp=4; IntAct=EBI-876651, EBI-346882;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome, centriole
CC       {ECO:0000250}. Golgi apparatus membrane; Peripheral membrane
CC       protein. Cell projection, bleb. Cytoplasm, cytoskeleton
CC       {ECO:0000250}. Cell membrane {ECO:0000250}. Cell projection,
CC       lamellipodium {ECO:0000250}. Cell projection, ruffle
CC       {ECO:0000250}. Note=Associated with the mother centriole and an
CC       intercentriolar linker. Colocalizes with ITGB1BP1 and ITGB1 at the
CC       cell membrane predominantly in lamellipodia and membrane ruffles,
CC       but also in retraction fibers. Localizes at the cell membrane in
CC       an ITGB1BP1-dependent manner (By similarity). A small proportion
CC       is associated with Golgi membranes. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Detected in blood platelets.
CC       {ECO:0000269|PubMed:8617235}.
CC   -!- DOMAIN: The C-terminal auto-inhibitory domain interferes with
CC       kinase activity. RHOA binding leads to a conformation change and
CC       activation of the kinase. Truncated ROCK1 is constitutively
CC       activated.
CC   -!- PTM: Autophosphorylated on serine and threonine residues.
CC       {ECO:0000269|PubMed:8617235}.
CC   -!- PTM: Cleaved by caspase-3 during apoptosis. This leads to
CC       constitutive activation of the kinase and membrane blebbing.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U43195; AAB02814.1; -; mRNA.
DR   EMBL; EF445027; ACA06069.1; -; Genomic_DNA.
DR   EMBL; BC113114; AAI13115.1; -; mRNA.
DR   EMBL; AB208965; BAD92202.1; -; mRNA.
DR   CCDS; CCDS11870.2; -.
DR   PIR; S69211; S69211.
DR   RefSeq; NP_005397.1; NM_005406.2.
DR   UniGene; Hs.306307; -.
DR   PDB; 1S1C; X-ray; 2.60 A; X/Y=947-1015.
DR   PDB; 2ESM; X-ray; 3.20 A; A/B=6-415.
DR   PDB; 2ETK; X-ray; 2.96 A; A/B=6-415.
DR   PDB; 2ETR; X-ray; 2.60 A; A/B=6-415.
DR   PDB; 2V55; X-ray; 3.70 A; A/C=1-406.
DR   PDB; 3D9V; X-ray; 3.30 A; A/B=6-415.
DR   PDB; 3NCZ; X-ray; 3.00 A; A/B/C/D=6-415.
DR   PDB; 3NDM; X-ray; 3.30 A; A/B/C/D=6-415.
DR   PDB; 3O0Z; X-ray; 2.33 A; A/B/C/D=535-700.
DR   PDB; 3TV7; X-ray; 2.75 A; A/B/C/D=6-415.
DR   PDB; 3TWJ; X-ray; 2.90 A; A/B/C/D=6-415.
DR   PDB; 3V8S; X-ray; 2.29 A; A/B/C/D=6-415.
DR   PDB; 4L2W; X-ray; 2.49 A; A/B/C/D=834-914.
DR   PDB; 4W7P; X-ray; 2.80 A; A/B/C/D=2-410.
DR   PDB; 4YVC; X-ray; 3.20 A; A/B=6-415.
DR   PDB; 4YVE; X-ray; 3.40 A; A/B=6-415.
DR   PDB; 5BML; X-ray; 2.95 A; A/B=6-415.
DR   PDB; 5F5P; X-ray; 3.57 A; C/D/E/F=834-913.
DR   PDB; 5HVU; X-ray; 2.80 A; A/B=6-415.
DR   PDBsum; 1S1C; -.
DR   PDBsum; 2ESM; -.
DR   PDBsum; 2ETK; -.
DR   PDBsum; 2ETR; -.
DR   PDBsum; 2V55; -.
DR   PDBsum; 3D9V; -.
DR   PDBsum; 3NCZ; -.
DR   PDBsum; 3NDM; -.
DR   PDBsum; 3O0Z; -.
DR   PDBsum; 3TV7; -.
DR   PDBsum; 3TWJ; -.
DR   PDBsum; 3V8S; -.
DR   PDBsum; 4L2W; -.
DR   PDBsum; 4W7P; -.
DR   PDBsum; 4YVC; -.
DR   PDBsum; 4YVE; -.
DR   PDBsum; 5BML; -.
DR   PDBsum; 5F5P; -.
DR   PDBsum; 5HVU; -.
DR   ProteinModelPortal; Q13464; -.
DR   SMR; Q13464; -.
DR   BioGrid; 112020; 41.
DR   DIP; DIP-35645N; -.
DR   IntAct; Q13464; 21.
DR   MINT; MINT-1195170; -.
DR   STRING; 9606.ENSP00000382697; -.
DR   BindingDB; Q13464; -.
DR   ChEMBL; CHEMBL3231; -.
DR   DrugBank; DB08756; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE.
DR   DrugBank; DB07876; (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE.
DR   DrugBank; DB04707; HYDROXYFASUDIL.
DR   GuidetoPHARMACOLOGY; 1503; -.
DR   iPTMnet; Q13464; -.
DR   PhosphoSitePlus; Q13464; -.
DR   SwissPalm; Q13464; -.
DR   BioMuta; ROCK1; -.
DR   DMDM; 47605999; -.
DR   EPD; Q13464; -.
DR   MaxQB; Q13464; -.
DR   PaxDb; Q13464; -.
DR   PeptideAtlas; Q13464; -.
DR   PRIDE; Q13464; -.
DR   Ensembl; ENST00000399799; ENSP00000382697; ENSG00000067900.
DR   GeneID; 6093; -.
DR   KEGG; hsa:6093; -.
DR   UCSC; uc002kte.4; human.
DR   CTD; 6093; -.
DR   DisGeNET; 6093; -.
DR   GeneCards; ROCK1; -.
DR   HGNC; HGNC:10251; ROCK1.
DR   HPA; CAB004562; -.
DR   HPA; HPA007567; -.
DR   HPA; HPA045639; -.
DR   MIM; 601702; gene.
DR   neXtProt; NX_Q13464; -.
DR   OpenTargets; ENSG00000067900; -.
DR   PharmGKB; PA34623; -.
DR   eggNOG; KOG0612; Eukaryota.
DR   eggNOG; ENOG410XR1Q; LUCA.
DR   GeneTree; ENSGT00760000118994; -.
DR   HOGENOM; HOG000017259; -.
DR   HOVERGEN; HBG053111; -.
DR   InParanoid; Q13464; -.
DR   KO; K04514; -.
DR   OMA; SMLDVDL; -.
DR   OrthoDB; EOG091G0BOR; -.
DR   PhylomeDB; Q13464; -.
DR   TreeFam; TF313551; -.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5627117; RHO GTPases Activate ROCKs.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; Q13464; -.
DR   SignaLink; Q13464; -.
DR   SIGNOR; Q13464; -.
DR   EvolutionaryTrace; Q13464; -.
DR   GeneWiki; ROCK1; -.
DR   GenomeRNAi; 6093; -.
DR   PMAP-CutDB; B0YJ91; -.
DR   PRO; PR:Q13464; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; ENSG00000067900; -.
DR   CleanEx; HS_ROCK1; -.
DR   ExpressionAtlas; Q13464; baseline and differential.
DR   Genevisible; Q13464; HS.
DR   GO; GO:0032059; C:bleb; IEA:UniProtKB-SubCell.
DR   GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030027; C:lamellipodium; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0001726; C:ruffle; ISS:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017049; F:GTP-Rho binding; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; TAS:ProtInc.
DR   GO; GO:0003383; P:apical constriction; IEA:Ensembl.
DR   GO; GO:0032060; P:bleb assembly; IEA:Ensembl.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0090002; P:establishment of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0097194; P:execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0050900; P:leukocyte migration; IDA:BHF-UCL.
DR   GO; GO:0050901; P:leukocyte tethering or rolling; IDA:BHF-UCL.
DR   GO; GO:0022614; P:membrane to membrane docking; IDA:BHF-UCL.
DR   GO; GO:0051451; P:myoblast migration; ISS:UniProtKB.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:1903347; P:negative regulation of bicellular tight junction assembly; IGI:UniProtKB.
DR   GO; GO:0035509; P:negative regulation of myosin-light-chain-phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; TAS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; TAS:UniProtKB.
DR   GO; GO:1903140; P:regulation of establishment of endothelial barrier; IMP:UniProtKB.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; TAS:UniProtKB.
DR   GO; GO:0045616; P:regulation of keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; TAS:UniProtKB.
DR   GO; GO:0007266; P:Rho protein signal transduction; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006939; P:smooth muscle contraction; TAS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   CDD; cd00029; C1; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015008; Rho-bd_dom.
DR   InterPro; IPR029876; ROCK1.
DR   InterPro; IPR020684; ROCK1/ROCK2.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR22988:SF51; PTHR22988:SF51; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08912; Rho_Binding; 1.
DR   PIRSF; PIRSF037568; Rho_kinase; 1.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50729; SSF50729; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Cell membrane;
KW   Cell projection; Coiled coil; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Golgi apparatus; Kinase;
KW   Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.4}.
FT   CHAIN         2   1354       Rho-associated protein kinase 1.
FT                                /FTId=PRO_0000086619.
FT   DOMAIN       76    338       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      341    409       AGC-kinase C-terminal.
FT   REPEAT      458    542       REM.
FT   DOMAIN     1118   1317       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   NP_BIND      82     90       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING    1228   1281       Phorbol-ester/DAG-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   REGION      368    727       Interaction with FHOD1.
FT                                {ECO:0000269|PubMed:18694941}.
FT   REGION      998   1010       RHOA binding.
FT   REGION     1115   1354       Auto-inhibitory.
FT   COILED      422    612       {ECO:0000255}.
FT   COILED     1011   1102       {ECO:0000255}.
FT   COMPBIAS    636    980       Glu-rich.
FT   ACT_SITE    198    198       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     105    105       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE       1113   1114       Cleavage; by caspase-3.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.4}.
FT   MOD_RES     647    647       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1105   1105       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES    1108   1108       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P70335}.
FT   MOD_RES    1328   1328       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT     108    108       S -> N (in dbSNP:rs55811609).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041055.
FT   VARIANT     773    773       T -> S (in dbSNP:rs45562542).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041056.
FT   VARIANT    1112   1112       T -> P (in dbSNP:rs35881519).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041057.
FT   VARIANT    1193   1193       P -> S (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041058.
FT   VARIANT    1217   1217       Q -> E (in dbSNP:rs2847092).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041059.
FT   VARIANT    1262   1262       R -> Q (in dbSNP:rs1045142).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041060.
FT   VARIANT    1264   1264       C -> R (in dbSNP:rs2663698).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041061.
FT   MUTAGEN    1113   1113       D->A: Abolishes cleavage by caspase-3.
FT                                {ECO:0000269|PubMed:11283607}.
FT   CONFLICT    170    170       V -> A (in Ref. 3; AAI13115).
FT                                {ECO:0000305}.
FT   CONFLICT    197    197       R -> G (in Ref. 3; AAI13115).
FT                                {ECO:0000305}.
FT   CONFLICT    220    220       C -> R (in Ref. 3; AAI13115).
FT                                {ECO:0000305}.
FT   CONFLICT    323    325       RLG -> GTR (in Ref. 5; BAD92202).
FT                                {ECO:0000305}.
FT   CONFLICT    521    521       D -> N (in Ref. 3; AAI13115).
FT                                {ECO:0000305}.
FT   CONFLICT    965    965       K -> R (in Ref. 3; AAI13115).
FT                                {ECO:0000305}.
FT   CONFLICT   1354   1354       S -> R (in Ref. 2; ACA06069).
FT                                {ECO:0000305}.
FT   HELIX         9     19       {ECO:0000244|PDB:3V8S}.
FT   HELIX        27     41       {ECO:0000244|PDB:3V8S}.
FT   HELIX        44     47       {ECO:0000244|PDB:3V8S}.
FT   HELIX        50     69       {ECO:0000244|PDB:3V8S}.
FT   HELIX        73     75       {ECO:0000244|PDB:3V8S}.
FT   STRAND       76     84       {ECO:0000244|PDB:3V8S}.
FT   STRAND       86     95       {ECO:0000244|PDB:3V8S}.
FT   TURN         96     98       {ECO:0000244|PDB:3V8S}.
FT   STRAND      101    108       {ECO:0000244|PDB:3V8S}.
FT   HELIX       109    114       {ECO:0000244|PDB:3V8S}.
FT   HELIX       121    130       {ECO:0000244|PDB:3V8S}.
FT   STRAND      139    144       {ECO:0000244|PDB:3V8S}.
FT   STRAND      146    153       {ECO:0000244|PDB:3V8S}.
FT   STRAND      157    160       {ECO:0000244|PDB:3NDM}.
FT   HELIX       161    167       {ECO:0000244|PDB:3V8S}.
FT   HELIX       172    191       {ECO:0000244|PDB:3V8S}.
FT   HELIX       201    203       {ECO:0000244|PDB:3V8S}.
FT   STRAND      204    206       {ECO:0000244|PDB:3V8S}.
FT   STRAND      212    214       {ECO:0000244|PDB:3V8S}.
FT   HELIX       217    219       {ECO:0000244|PDB:4YVE}.
FT   STRAND      227    230       {ECO:0000244|PDB:3V8S}.
FT   HELIX       238    240       {ECO:0000244|PDB:3V8S}.
FT   HELIX       243    247       {ECO:0000244|PDB:3V8S}.
FT   TURN        248    252       {ECO:0000244|PDB:3V8S}.
FT   STRAND      254    256       {ECO:0000244|PDB:3V8S}.
FT   HELIX       258    273       {ECO:0000244|PDB:3V8S}.
FT   HELIX       283    291       {ECO:0000244|PDB:3V8S}.
FT   HELIX       293    296       {ECO:0000244|PDB:3V8S}.
FT   HELIX       307    316       {ECO:0000244|PDB:3V8S}.
FT   HELIX       320    322       {ECO:0000244|PDB:3V8S}.
FT   TURN        324    327       {ECO:0000244|PDB:2ETR}.
FT   HELIX       329    333       {ECO:0000244|PDB:3V8S}.
FT   HELIX       336    338       {ECO:0000244|PDB:3V8S}.
FT   TURN        345    347       {ECO:0000244|PDB:3TV7}.
FT   HELIX       348    350       {ECO:0000244|PDB:3V8S}.
FT   HELIX       365    367       {ECO:0000244|PDB:3NCZ}.
FT   HELIX       392    394       {ECO:0000244|PDB:3V8S}.
FT   STRAND      399    402       {ECO:0000244|PDB:2ETR}.
FT   HELIX       535    540       {ECO:0000244|PDB:3O0Z}.
FT   HELIX       544    691       {ECO:0000244|PDB:3O0Z}.
FT   HELIX       840    902       {ECO:0000244|PDB:4L2W}.
FT   HELIX       947    982       {ECO:0000244|PDB:1S1C}.
FT   HELIX       984   1011       {ECO:0000244|PDB:1S1C}.
SQ   SEQUENCE   1354 AA;  158175 MW;  93078CBB009A6F27 CRC64;
     MSTGDSFETR FEKMDNLLRD PKSEVNSDCL LDGLDALVYD LDFPALRKNK NIDNFLSRYK
     DTINKIRDLR MKAEDYEVVK VIGRGAFGEV QLVRHKSTRK VYAMKLLSKF EMIKRSDSAF
     FWEERDIMAF ANSPWVVQLF YAFQDDRYLY MVMEYMPGGD LVNLMSNYDV PEKWARFYTA
     EVVLALDAIH SMGFIHRDVK PDNMLLDKSG HLKLADFGTC MKMNKEGMVR CDTAVGTPDY
     ISPEVLKSQG GDGYYGRECD WWSVGVFLYE MLVGDTPFYA DSLVGTYSKI MNHKNSLTFP
     DDNDISKEAK NLICAFLTDR EVRLGRNGVE EIKRHLFFKN DQWAWETLRD TVAPVVPDLS
     SDIDTSNFDD LEEDKGEEET FPIPKAFVGN QLPFVGFTYY SNRRYLSSAN PNDNRTSSNA
     DKSLQESLQK TIYKLEEQLH NEMQLKDEME QKCRTSNIKL DKIMKELDEE GNQRRNLEST
     VSQIEKEKML LQHRINEYQR KAEQENEKRR NVENEVSTLK DQLEDLKKVS QNSQLANEKL
     SQLQKQLEEA NDLLRTESDT AVRLRKSHTE MSKSISQLES LNRELQERNR ILENSKSQTD
     KDYYQLQAIL EAERRDRGHD SEMIGDLQAR ITSLQEEVKH LKHNLEKVEG ERKEAQDMLN
     HSEKEKNNLE IDLNYKLKSL QQRLEQEVNE HKVTKARLTD KHQSIEEAKS VAMCEMEKKL
     KEEREAREKA ENRVVQIEKQ CSMLDVDLKQ SQQKLEHLTG NKERMEDEVK NLTLQLEQES
     NKRLLLQNEL KTQAFEADNL KGLEKQMKQE INTLLEAKRL LEFELAQLTK QYRGNEGQMR
     ELQDQLEAEQ YFSTLYKTQV KELKEEIEEK NRENLKKIQE LQNEKETLAT QLDLAETKAE
     SEQLARGLLE EQYFELTQES KKAASRNRQE ITDKDHTVSR LEEANSMLTK DIEILRRENE
     ELTEKMKKAE EEYKLEKEEE ISNLKAAFEK NINTERTLKT QAVNKLAEIM NRKDFKIDRK
     KANTQDLRKK EKENRKLQLE LNQEREKFNQ MVVKHQKELN DMQAQLVEEC AHRNELQMQL
     ASKESDIEQL RAKLLDLSDS TSVASFPSAD ETDGNLPESR IEGWLSVPNR GNIKRYGWKK
     QYVVVSSKKI LFYNDEQDKE QSNPSMVLDI DKLFHVRPVT QGDVYRAETE EIPKIFQILY
     ANEGECRKDV EMEPVQQAEK TNFQNHKGHE FIPTLYHFPA NCDACAKPLW HVFKPPPALE
     CRRCHVKCHR DHLDKKEDLI CPCKVSYDVT SARDMLLLAC SQDEQKKWVT HLVKKIPKNP
     PSGFVRASPR TLSTRSTANQ SFRKVVKNTS GKTS
//
